PDE5A and melanoma: However, notwithstanding the low number of patients enrolled in these trials, the positive immunomodulatory actions of PDE5 inhibition were associated with no clinical benefits (Supplementary Figure 1), although disease stabilization was reported for few patients in the melanoma trial and in case reports (64, 65).